Surgical treatment of malignant peritoneal mesothelioma: past, present, and future

Our plain-English summary of Surgical treatment of malignant peritoneal mesothelioma: past, present, and future, by H.R. Alexander (Annals of Surgical Oncology, 2010).

The study

• Author: H.R. Alexander
• Journal: Annals of Surgical Oncology
• Published: 2010;17(1):21-2
• Type of article: Comment, Editorial
• Cited by: 7 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Summary of the article

In this editorial, the author discussed the surgical treatment of malignant peritoneal mesothelioma (MPM) and commented on a study by Baratti and colleagues published in the same issue. He noted that only 10–15% of patients with mesothelioma have the peritoneal form, about 300–400 cases a year in the USA, and that many trials of systemic agents had not separated peritoneal from pleural disease. He reviewed early reports. These included Borow's report of the association between asbestos exposure and mesothelioma, and a 1973 report of four patients treated with cytoreduction and whole-abdominal radiotherapy, two of whom survived more than 5 years. He also cited a series of 37 patients treated at the Dana Farber Cancer Institute and Brigham and Women's Hospital between 1965 and 1984. He described the rationale for cytoreduction combined with hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC). Summarizing the Baratti study of 83 patients, he reported that nodal metastases were found in 20% of 15 patients whose nodes were routinely sampled and in 40% of a group with enlarged, suspicious nodes. Epithelioid histology, low mitotic count, complete gross cytoreduction and pathologically negative nodes were independent factors associated with increased survival. He stated that the predictive value of nodal status needed validation in additional studies. He concluded that meaningful progress required collective and cooperative efforts rather than single-institution reports.

PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

In plain English

This was a short editorial, not an original study, about surgery for malignant peritoneal mesothelioma (MPM), a cancer of the lining of the abdomen. The author described MPM as rare, with about 300–400 cases a year in the USA. The editorial discussed a separate study by Baratti and colleagues at the National Cancer Institute of Italy. That study looked at lymph node spread in patients treated with cytoreduction, which is surgery to remove visible tumor, plus HIPEC, which is heated chemotherapy given into the abdomen during surgery. As the author summarized it, node spread was found in 20% of 15 patients whose nodes were routinely sampled and in 40% of a group with enlarged, suspicious nodes. Across 83 patients treated over 13 years, epithelioid tumor type, low mitotic count, complete removal of visible tumor and cancer-free nodes were each independently associated with longer survival. The author noted it was unclear whether node spread reflected tumor amount or tumor biology, and said the value of node status needs testing in more studies. The author concluded that progress requires cooperative research across centers. Asbestos appears only as historical background.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Editorial commenting on a separate study (Baratti et al.) published in the same journal issue; no original data
• Who was studied: No study population of its own; the editorial discusses Baratti and colleagues' series of 83 patients with diffuse MPM treated over a 13-year interval at the National Cancer Institute of Italy
• Exposure: No exposure studied; the treatment discussed is cytoreduction with hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC). Asbestos is mentioned only as historical background.
• Main results:
  • The author stated, as background, that MPM is rare, with approximately 300–400 cases in the USA annually
  • As reported by the author from Baratti et al.: among 15 patients whose lymph nodes were routinely sampled, 20% had nodal metastases, compared with 40% in a cohort whose nodes appeared enlarged and suspicious
  • As reported by the author from Baratti et al.: in the overall series of 83 patients, epithelioid histology, low mitotic count, complete gross cytoreduction and pathologically negative nodes were independent factors associated with increased survival
  • As reported by the author from Baratti et al.: a higher peritoneal cancer index (a measure of tumor burden in the abdomen) was associated with node positivity
  • As reported by the author from Baratti et al.: no patient with lymph node metastases developed recurrences in nodal basins on follow-up
• The authors' conclusion: The author concluded that meaningful advances require moving from single-institution reports to collective and cooperative efforts in studying this rare disease
• Limitations the authors state:
  • The author stated it was not clear from Baratti et al.'s paper whether lymph node metastases reflected advanced tumor burden or tumor biology
  • The author stated that whether nodal status can be used routinely to predict outcome needs to be validated in additional studies
  • The author noted the small number of patients (83 over 13 years) even at a center of expertise

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma, Peritoneal mesothelioma.

Medical terms in this study, explained in our Lexicon: Peritoneal Mesothelioma, Mesothelioma, Asbestos Exposure, Cytoreductive Surgery, Brigham and Women's Hospital, Chemotherapy, HIPEC, Epithelioid.

Related studies

• Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future — G. Reid, T.G. Johnson, et al. (2020)
• Asbestos use and asbestos-related diseases in Asia: past, present and future — G.V. le, K. Takahashi, et al. (2011)
• Exposure to asbestos: past, present and future — E. Pira, F. Donato, et al. (2018)
• The ghost of public health journalism: past, present, and future — G.S. Cooper, R.C. Brown (2010)
• ASO Author Reflections: Postoperative Radiotherapy for Patients with Mesothelioma-Past, Present, and Future — G.D. Lewis, B.S. Teh (2019)
• Surgical treatment of peritoneal carcinomatosis: current treatment modalities — Y. Kulu, B. Müller-Stich, et al. (2014)

Browse more research in Annals of Surgical Oncology, or return to medical research.